Clinical trial ACTRN12619000623190
Status: Recruiting (according to the registry)Phase 2Latest change: Source: ANZCTR (Australia, New Zealand) (via WHO ICTRP)
What's on this page?
This record’s status may be out of date
The trial was registered in April 26, 2019 and still shows as "recruiting" in the registry. Status information in other countries’ registries is often not updated; the trial may have ended or stopped. For current information, check the record itself.
Information in the record
Original title: An open label, study to evaluate the safety of Cannabidiol (CBD) for the prevention of Acute Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic cell transplantation.
- Record number
- ACTRN12619000623190
- Registry
- ANZCTR (Australia, New Zealand) (via WHO ICTRP)
- Status
- Recruiting (according to the registry)
- Type and phase
- Clinical trial, phase 2
- Participants
- Target: 36
- Condition (as registered)
- Acute Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Cancer - Other cancer types, Blood - Haematological diseases
- Countries
- Australia, Israel
- Topic in the guide
- Cancer Treatment
Timeline
According to the ANZCTR (Australia, New Zealand) (via WHO ICTRP) record. Future dates are the investigator’s estimates and may change.
- Registration: April 26, 2019
History
We check the record once a month via WHO ICTRP; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Recruiting.
Results
No results have been published yet. When they are, they will appear here. A trial being under way does not mean CBD works for this condition; only the results can show that.
All ongoing trials · Cancer Treatment: guide page · Thinking of taking part? Which specialist to see